DiaCarta is a leading translational genomics and personalized diagnostics company based in Pleasanton, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.
SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology and infectious disease tests announced today that the company has received CE-IVD mark for their newly developed QuantiVirus™ SARS-CoV-2 & Flu A/B Test.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.
linkedinfacebooktwitterInfluenza and COVID-19: what are they in common? Currently, the two most important respiratory viruses the healthcare authority is paying attention to are SARS-COV-2 (causing COVID-19) and influenza A and B viruses (Flu A and B). The Flu A and B...
linkedinfacebooktwitterCancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone....